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PERSPECTIVES ON DRUGS 
Strategies to prevent diversion 
of opioid substitution treatment 
medications
Opioid dependence is a complex health condition that usually 
requires long-term treatment. It tends to be managed with the 
use of medications in a similar way to other chronic illnesses 
characterised by possible frequent relapses (McLellan et al., 
2000; WHO, 2004). International guidelines (WHO, 2009; 
Department of Health, 2007) recommend opioid substitution 
treatment (OST), such as methadone and buprenorphine, 
as the main medications for treating opioid dependence. 
The effectiveness of OST in reducing the risks of overdose 
and mortality, injecting risk behaviour and illegal opioid use 
and criminality, and in improving quality of life and health, is 
well established internationally (Amato et al., 2008; Gowing 
et al., 2008; Mattick et al., 2008; Lawrinson et al., 2008; 
Schaub et al., 2010). An estimated 645 000 opioid users 
received substitution treatment in the European Union in 
2014 (683 000 including Norway and Turkey), and numbers 
have fallen by around 50 000 since 2010. Methadone is 
the most commonly prescribed opioid substitution drug, 
received by over two-thirds (70 %) of substitution clients. A 
further 28 % of clients are treated with buprenorphine-based 
medication, which is the principal substitution drug in seven 
countries. Other substances, such as slow-release morphine 
or diacetylmorphine (heroin), are more rarely prescribed, being 
received by an estimated 2 % of substitution clients in Europe.
Substitution treatment is regulated by Member States using 
different types of national law. In almost all countries the 
admission criteria for substitution treatment programmes are 
laid down either in national laws or in ministerial decrees or 
guidelines. The laws usually also define who is permitted to 
prescribe treatment. These are primarily doctors in treatment 
centres, though in some countries any doctor or certain 
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the treatment of opioid dependence 
represents a key evidence-based response 
to heroin problems in Europe. However, 
the diversion of these medicines from 
their intended use in drug treatment to 
non-medical use and sale on illicit drug 
markets is a cause for concern. The use of 
diverted substances has been associated 
with fatal and non-fatal overdose 
and an increased incidence of opioid 
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and what current measures are being 
implemented to reduce it, and considers 
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trained or accredited doctors may prescribe. Maximum doses 
are rarely defined by law.
Like any prescription medicines, OST medications can be 
diverted, despite the existence of legislative controls on their 
availability. Diversion can be regarded as the inappropriate 
use of prescribed medicine and has been defined as the 
unsanctioned supply of regulated pharmaceuticals from legal 
sources either to the illicit drug market or to a user for whom 
the drugs were not intended (Larance et al., 2014; Inciardi et 
al., 2007). Diversion can occur at all points in the drug delivery 
process: from the original manufacturing site to the wholesale 
distributor, the physician’s office, the retail pharmacy or the 
patient (Inciardi et al., 2007). Diversion methods include: the 
illegal sale and recycling of prescriptions by physicians and 
pharmacists; the ‘doctor shopping’ phenomenon (Delorme, 
2016), whereby individuals consult more than one doctor 
to obtain multiple prescriptions; theft (including stealing 
insurance cards to obtain multiple prescriptions), forgery, or 
alteration of prescriptions by patients; robberies and thefts 
from manufacturers, distributors, and pharmacies; and thefts 
of institutional drug supplies (Cicero et al., 2011).
In the last two decades OST diversion has been documented 
in countries all over the world (Humeniuk et al. 2003, 
Jenkinson et al. 2005, Cicero et al. 2011, Johnson et al. 
2015). Although the diversion of OST medications has been 
described as a growing problem in recent years, there has 
been little systematic monitoring or data collection able to 
quantify the magnitude of the problem. There is also a lack 
of empirical data that might be used for making regulatory 
decisions and for developing prescription drug prevention and 
risk management plans (Cicero et al., 2013). Various reasons 
have been described in the literature to explain diversion, 
including (among drug users) attempting to help other users 
who are not accessing treatment (Havnes 2013, Johnson 
2015). Nonetheless, an overview of available studies suggests 
that the use of diverted substances has been associated 
with three consequences: fatal and non-fatal overdose; an 
increased incidence of opioid dependence (particularly in 
jurisdictions where heroin is scarce); and compromising the 
public acceptance of treatment programmes (Bell, 2010).
The United States has seen an unprecedented rise in the 
misuse of prescription opioids and the findings point to 
an association with overdose deaths and admissions to 
emergency departments and treatment facilities among 
people using opioids (Yokell et al., 2011;Weimer et al., 2011; 
Rosca et al., 2012; Selden et al., 2012; Huang et al., 2013; 
Richert et al., 2011; Cicero et al., 2011; Wikner et al., 2014).
Longitudinal studies of methadone-related deaths conducted 
between 2009 and 2012 in the United Kingdom have 
illustrated the risks of diverted methadone. For example, 
research has shown that while a significant minority of cases 
occurred in the in-treatment population, the majority of cases 
happened in the general population (Corkey, 2013; Ghodse, 
2010, 2011, 2012, cit. in Marteau, 2015).
Several studies have found a strong correlation between the 
levels of medical and non-medical use of prescription opioids 
(ALICE-RAP, 2013). Non-medical prescription opioid use 
refers to any use that is not prescribed, or use in a manner 
other than that intended by the prescriber (Compton et al., 
2016). This includes: taking increased doses of the opioid; 
taking opioids for a longer period of time than intended; taking 
opioids that were prescribed for another person; obtaining 
prescriptions under false premises; and obtaining the 
medication outside of the medical system (ALICE-RAP, 2013). 
As the medical use of opioids to treat chronic and acute pain 
has expanded in recent decades, in particular in the United 
States (Compton et al., 2016) there is concern that this might 
trigger increased diversion and non-medical use of opioid 
medications.
In European countries methadone and buprenorphine are the 
prescription opioids most commonly misused by those who 
start treatment for drug misuse. Overall, non-medical use of 
methadone is the most commonly reported opioid addiction 
other than heroin, followed by buprenorphine. Respectively, 
these drugs account for 60 % and 30 % of all treatment 
demands from clients whose primary drug problem relates 
to opioids other than heroin. In some countries, for example 
Estonia and Finland, non-heroin opioids now represent the 
most common form of problem opioid use (EMCDDA, 2016).
I  Strategies to reduce medication diversion  
Certain interventions have been developed with the aim 
of minimising the diversion of OST. These include the use 
of misuse-deterrent formulations, supervision of doses for 
people who are not stable in treatment, the development 
of clinical prescribing guidelines and education activities to 
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ensure quality of care. Interventions are aimed at patients, 
physicians and distribution systems. It is likely that a 
combined approach and treatment plans tailored to patient 
needs will be most effective, although evidence supporting 
this is not yet available.
Misuse-deterrent formulations of opioids are being applied 
in different ways. Opioid formulations have been developed 
with misuse-deterring properties, such as Suboxone, a 
combination of buprenorphine and naloxone. Dilution of 
methadone liquid resulting in large-volume packaging may 
also discourage injecting. 
Educating physicians and patients can be effective in 
reducing the risk of diversion. Physicians can be educated 
on safe opioid prescribing, including comprehensive initial 
assessment and regular monitoring of patients. Patients 
can be provided with health information and educated on 
safe use, including information about appropriate storage 
and disposal of pharmaceuticals that are no longer needed. 
In a US study a sustained positive change in physician 
practice behaviours and improved knowledge was found 
regarding clinical practice behaviours on dosing and setting 
limits/revising treatment plans following a four-hour course 
(EMCDDA, 2016).
Electronic medicine dispensers can promote safe opioid 
prescribing and reduce medical errors, and have been 
implemented in the United States and some other countries. 
A small Finnish study evaluating the use of electronic 
medical dispensers in 37 OST patients found some evidence 
that electronic dispensers had prevented diversion of 
buprenorphine-naloxone. Most patients felt it was safer to 
store take-home doses in electronic dispensers than in paper 
sachets (Uosukainen et al., 2013).
Supervision of OST dosing is likely to reduce the diversion 
of OST. Clinical guidelines that cover methadone and 
buprenorphine treatment in the United Kingdom, and 
in Canada (Department of Health, 2007; CAMH, 2011) 
recommend initial supervision of OST. Subsequent suitability 
for unsupervised dosing is based on assessment of a client’s 
social functioning (employment, housing), on cessation of 
regular injecting, on not presenting intoxicated for dosing 
and on low levels of ongoing drug misuse (confirmed by 
urine toxicology). In addition, guidelines produced by the 
World Health Organization on the combination of specific 
pharmacological and psychosocial interventions (WHO, 
2009) recommend supervision of dosing for both methadone 
and buprenorphine to reduce the risk of diversion in opioid 
dependents, especially at the start of treatment; take-away 
doses may be provided when patients are considered stable 
and the risk of diversion is low.
I  Key definitions 
Opioid substitution therapy (OST) (see the video) 
indicates an intervention in which patients who are 
dependent on fast-acting opioids (such as heroin) 
are administered slow-acting opioids instead (such 
as methadone and buprenorphine). The treatment is 
described using a range of terms, including ‘substitution’, 
‘maintenance’, ‘agonist’ and ‘pharmacologically assisted’. 
The term OST has limitations because it does not describe 
the nature of the medications involved, which do not 
necessarily have substitutive effects for illicit opioids, but 
may instead reduce cravings and support the control of 
addictive behaviour.
Diversion of a medicine is defined as the intentional 
transfer of a controlled drug from legitimate distribution 
and dispensing into illegal channels.
Misuse is defined as the use of a medication other than as 
directed or as indicated, whether wilful or unintentional, 
and whether it results in harm or not.
What do the guidelines say? 
Most of the available guidelines on the treatment of 
opioid dependence agree on the importance of providing 
access to opioid substitution therapy and suggest that the 
professional responsible for the prescription should assess 
the possible risks of diversion on a case-by-case basis.
Some examples of guidelines have been selected from the 
inventory of the ‘Best practice’ portal.
The World Health Organization’s Guidelines for the 
psychosocially assisted pharmacological treatment of 
opioid dependence (2009) address the risks of diversion 
in various parts of the guidelines and in some specific 
recommendations. In particular, they recommend offering 
medication take-home doses when the dose itself and the 
social situation is stable and there is a low risk of diversion 
for illegitimate purposes.
The same recommendation suggests monitoring the 
safety of the treatment service, including the extent of 
medication diversion.
The recommendations for the treatment of individual 
patients include:
• supervision of methadone and buprenorphine doses 
in the early phase of treatment (the recommendation is 
strong for the panel developing the guidelines but based 
on a low level of evidence);
• take-away doses may be provided for patients when 
the benefits of reduced frequency of attendance are 
considered to outweigh the risk of diversion, subject to 
regular review (the recommendation is strong for the panel 
developing the guidelines but based on a low level of 
evidence).
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A study of dependence treatment centres in Italy found 
that: take-home doses in the context of a behavioural 
contingency management programme did not increase 
unlawful behaviour; and patients in a non-contingent take-
home programme were over six times more likely to sell their 
methadone on the black market than those in a six days per 
week supervised daily consumption programme (Gerra et al., 
2011). A study in England and Scotland looked at mortality 
rates for methadone-related overdoses during a 16-year 
period. It found that a reduction of overdoses corresponded 
to the introduction of facilities for supervised consumption of 
methadone (Strang, 2010).
Monitoring patients is another way to reduce diversion. 
Clinical guidelines recommend the surveillance and 
monitoring of patients in OST with the aim of reducing the 
risk of medication diversion (see ‘Facts and figures’). Such 
monitoring may include toxicology screening/drug testing, 
pill counts, unannounced monitoring/random call-backs 
(especially for those with extended take-home doses) and 
supervised ingestion (Martin et al., 2014).
Diversion control systems target the wider distribution 
system. A US review on existing drug diversion control 
systems (Deyo, 2014) distinguished two basic goals: first, 
to limit access to the controlled substances only to those 
with a legitimate need for access; and second, to establish, 
through records and reporting, the ability to track and identify 
instances in which the access controls are compromised 
(Deyo, 2014).
In the United States, since 2005, databases have been 
established in 38 states that collect information on the 
prescriber, pharmacy, product name, concentration, dose and 
amount of controlled substance dispensed (Prescription Drug 
Monitoring Programmes (PDMP)). Similar programmes exist 
in Australia and some parts of Europe. Although some studies 
have suggested that these programmes have a substantial 
impact on reducing the supply of monitored drugs and 
the rates of drug misuse, their quality is variable, and their 
success relies on a variety of factors.
I  Current evaluation findings
To date, it is not yet clear which of the approaches outlined 
above are most effective in preventing the diversion of OST 
medications. Most interventions have occurred on an ad hoc 
basis, and commentators have emphasised the need for 
systematic evaluations of their effects on reducing diversion 
in the interest of evidence-based policy and public health. It 
also remains to be established whether policies contribute 
to a reduction of diversion when they are included in an 
integrated drug control system or whether certain strategies 
constitute cost-effective stand-alone interventions.
A summary of evidence is critical in order to support informed 
decision-making on which elements of anti-diversion systems 
are effective in reducing opioid diversion, and which require 
further research.
An EMCDDA analysis identified six studies evaluating at 
different levels some strategies for the prevention and/or 
reduction of OST diversions (see table below). These studies 
addressed various targets, such as: patients, physicians or the 
system of OST distribution.
The Canadian guidelines on buprenorphine/naloxone 
for opioid dependence (2011) recommend that, when 
making decisions regarding the provision of take-home 
doses of buprenorphine/naloxone, providers should 
use a clinical risk stratification strategy (as described in 
the clinical considerations) that aims to support patient 
autonomy while at the same time respecting patient 
and public safety. (Level III, Grade A, meaning that the 
level of evidence is low but the panel agrees on a strong 
recommendation.)
At the European level, for example the European Centre 
for Disease Prevention and Control (ECDC)–EMCDDA 
joint Guidelines on prevention and control of infectious 
diseases among people who inject drugs mention that 
‘opioid substitution medications can be dispensed in 
clinics, in specialised centres in the community or in 
pharmacies. In all settings, the direct supervision of the 
patient taking the medications can prevent diversion of 
drugs to the illicit market. However, take-home doses 
allow patients to follow family- or work-related obligations 
and lead a more “normal” life. For all undergoing such 
treatment, regular medical examinations are an essential 
requirement’.
Motion graphic explaining opioid substitution treatment, available on the EMCDDA 
website: www.emcdda.europa.eu/topics/pods/preventing-diversion-of-opioid-
substitution-treatment
I  Interactive element: motion graphic
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Target 
group
Possible strategies 
to reduce/control 
diversion
Synthesis of evidence References
P
at
ie
n
ts
Misuse-deterrent drug 
formulations
Significantly fewer methadone clients reported diversion compared 
to buprenorphine-naloxone tablet clients.
Addition of naloxone reduces, but does not abolish, diversion.
Clinicians need to employ patient selection for prescribing of doses 
without observation, and monitor patients regularly, rather than 
relying solely upon the formulation of the medication to minimise 
risk.
Larance et al, 2014 
(Australia; N=543 
patients)
Bell, 2011 
(United Kingdom, 
Australia, United 
States, France; N= 
not applicable)
Health education, 
including safe storage
Doctors prescribing opioids for pain treatment should be trained on 
how to regularly monitor their patients. 
Hahn, 2011 
Supervision of OST 
dosing
Early non-contingent take-home patients were over six times more 
likely to sell their medication or part of it on the black market once or 
twice a week.
Introduction of supervised methadone dosing was followed by 
substantial declines in deaths related to overdose of methadone 
(Scotland and England).
Gerra, 2011 
(Italy; N=300 
patients)
Strang, 2010 
(Scotland, England 
death records 
1993–2008; N=5 
624 death records)
Monitoring patients, 
e.g. toxicology tests, pill 
counts, unannounced 
monitoring and observed 
ingestion
Some recommendations exist for the identification of ‘red flag’ 
behaviours that indicate possible diversion. In these cases: 
preference for misuse-deterrent formulations, toxicology, 
examination of injecting sites and child protection assessment, 
pill counts, observed ingestion and advise patients regarding 
appropriate medication storage. 
Martin, 2014 
(Australia; N= not 
applicable)
Bell, 2011 
(United Kingdom, 
Australia, United 
States, France; N= 
not applicable)
P
h
ys
ic
ia
n
s
Continuing medical 
education including safe 
opioid (buprenorphine) 
prescribing, initial 
patient assessment and 
monitoring for physicians 
in office-based opioid 
dependence treatment
Positive change in physician practice behaviours and improved 
knowledge that was sustained.
Lofwall, 2011 
(US; N=311 
physicians)
Electronic medicine 
dispensers (EMD)
The use of EMDs provided a feasible method for improving the safe 
storage of take-home doses of buprenorphine-naloxone. 
Uosukainen 2013 
(Finland; N=56)
S
ys
te
m
 o
f 
d
is
tr
ib
u
ti
on
To limit access to the 
controlled substances 
only to those with a 
legitimate need for 
access; to establish the 
ability to track and identify 
instances in which the 
access controls are 
compromised
Six systems described, of varying utility as reported by users; 
monitoring programmes exist in 44 US states and some other 
countries, their quality is variable, and their effects on public health 
are being explored.
Clinical guidelines and clinical audit to enhance compliance with 
guidelines are helpful in maintaining the quality and integrity of the 
treatment system, and can contribute to keeping diversion within 
acceptable levels.
Medication management system should ensure that medications are 
available to those who need it, while monitoring for and preventing 
possible diversion.
Deyo, 2014 
(Prescription 
monitoring systems 
in 44 states)
Bell, 2011 
(UK, Australia, US, 
France; N= not 
applicable)
UNODC, 2011 
(UNODC discussion 
paper)
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I Conclusion
It is difficult to estimate the extent of diversion from opioid 
substitution treatment in Europe. Nonetheless, given the 
important role substitution treatment has in Europe it is 
critical that a more systematic understanding of what is 
effective is used to support treatment systems. Current 
evidence suggests that the risks of diversion of OST 
medications from treatment settings can be reduced by the 
application of clinical standards and guidelines for appropriate 
dosing, supervision of doses for people who are not stable in 
treatment, for identification of patients ready for unobserved 
doses and education activities to ensure quality of care. Other 
strategies include the use of alternative formulations and 
dilution of take-away OST doses.
There is a need for more systematic evaluation of the different 
strategies that are being used to reduce diversion. To support, 
this observational studies or randomised controlled trials 
that systematically compare the different strategies should 
be used to identify the most effective interventions. This will 
allow the development of best practices that can be more 
widely rolled out. A summary of evidence is needed to support 
informed decision-making on policies for diversion and to 
define which elements of diversion systems are effective in 
reducing opioid diversion.
Substitution treatment, typically combined with 
psychosocial interventions, is the most common treatment 
for opioid dependence. This approach is supported by the 
available evidence, with positive outcomes found in respect 
of treatment retention, reduced illicit opioid use, reported 
risk behaviour, and reductions in drug-related harms and 
mortality. 
 
Evidence base 
 
OST, combined with psychosocial support, helps patients 
stay in treatment and reduces use and mortality. It also 
has a positive impact on the mental health of patients. 
Methadone and buprenorphine are the recommended 
pharmacological treatments. Taking into account clinical 
practice, methadone is superior to buprenorphine in 
retaining people in treatment, particularly in the first weeks, 
and equally suppresses illicit opioid use. 
 
There is a strong evidence base for the use of OST, 
including the following studies, and in the last update of the 
Guidelines for the psychosocially assisted pharmacological 
treatment of opioid dependence (WHO, 2009). Methadone 
substitution treatment was found in a systematic review of 
three randomised controlled trials (RCTs) (N=505) (WHO, 
2009) to be more effective than opioid withdrawal, followed 
by placebo, in increasing retention in treatment and 
reducing illicit opioid use. Observational studies found the 
mortality rate in methadone treatment to be approximately 
one-third the rate out of treatment. Methadone was 
found in one RCT (N=253) to reduce the risk of HIV 
infection by approximately 50 % and a similar reduction 
in seroconversion rates 
was found in three 
observational studies 
(N=43.035) (RR 0.36, 95 
% CI 0.19 to 0.66) when 
compared to withdrawal 
or no treatment. 
 
Buprenorphine 
substitution treatment 
was found to be more 
effective than placebo in 
a synthesis of evidence 
(WHO, 2009). More 
recently, in a systematic 
review (Mattick et al., 
2014) it was found to improve retention in treatment and 
reduce the number of morphine-positive urines only at high 
doses 
 
Methadone treatment plus psychosocial intervention 
compared with methadone treatment only was found in 
a systematic review of three studies (N=388), to be more 
effective in reducing heroin use (RR 0.69, 95 % CI 0.53 to 
0.91) (WHO, 2009). Combined psychosocial (contingency 
management, community reinforcement, psychotherapeutic 
counselling and family therapy) and pharmacological 
assistance have been found to be effective in a systematic 
review of five randomised control trials (N=184 participants) 
in increasing rates of completion of treatment and reducing 
rates of relapse at follow-up (WHO, 2009). 
The evidence for opioid substitution treatment in Europe  
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